chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Vaccine administered to a 16 years old patient; Felt little crappy; This spontaneous case was reported by a consumer and describes the occurrence of PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (Vaccine administered to a 16 years old patient) and FEELING ABNORMAL (Felt little crappy) in a 16-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On 26-Apr-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 26-Apr-2021, the patient experienced PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (Vaccine administered to a 16 years old patient) and FEELING ABNORMAL (Felt little crappy). On 26-Apr-2021, FEELING ABNORMAL (Felt little crappy) had resolved. At the time of the report, PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (Vaccine administered to a 16 years old patient) outcome was unknown.            No concomitant medications were provided.  No treatment drugs were reported.
i have never had any issues with my skin. I started noticing small dry patches early on after taking the vaccine. then 2 months pass and i have sever rash outbreaks in various places on my body. First it was on my ankles, then that just disappeared; then i had patches of dry skin on my neck; then on my arms, and finally my hands (BOTH) broke out in full blown sever eczema. Not just mild symptoms, sever, symptoms where i cannot grip or hold objects, severe itching and swelling.
Having hard time breathing; Hardly slept; This spontaneous case was reported by a consumer and describes the occurrence of DYSPNOEA (Having hard time breathing) and INSOMNIA (Hardly slept) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 15-Jan-2021, the patient experienced DYSPNOEA (Having hard time breathing) and INSOMNIA (Hardly slept). At the time of the report, DYSPNOEA (Having hard time breathing) and INSOMNIA (Hardly slept) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medications were reported. No treatment related information has been reported.; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.
Information has been received from a medical assistant concerning herself (demographics not provided). On 18-MAY-2007 she was vaccinated intramuscularly with the first dose of Gardasil (Lot# no provided). On 18-JUN-2007 the patient was vaccinated intramuscularly with the second dose of Gardasil (Lot# not provided). The patient reported that since the second vaccination on 18-JUN-2007 she has experienced intermittent nausea and cramping. The patient has no sought medical attention. No further information is available.
Paint at injections site on left arm; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE PAIN (Paint at injections site on left arm) in a 63-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 025J20A) for COVID-19 vaccination.     The patient's past medical history included Asthma. Concomitant products included LISINOPRIL, MULTIVITAMIN & MINERAL and ACETYLSALICYLIC ACID (BABY ASPIRIN) for an unknown indication.    On 06-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 07-Jan-2021, the patient experienced VACCINATION SITE PAIN (Paint at injections site on left arm). On 10-Jan-2021, VACCINATION SITE PAIN (Paint at injections site on left arm) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant medication also includes Thyroid medicine, Allergy medicine and Albuterol inhaler.   This case was linked to MOD-2021-015729 (Patient Link).
pt recv vax 7JUL98 & pt seen by 19JUL98 reports fever x 4 days then rash & dry lips, dec appetite x 2 days;
Vaccine went into 2-8 Celsius thaw state on or about 24-Dec-2021 and administered on 05-Feb-2022; Vaccine went into 2-8 Celsius thaw state on or about 24-Dec-2021 and administered on 05-Feb-2022; This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Vaccine went into 2-8 Celsius thaw state on or about 24-Dec-2021 and administered on 05-Feb-2022) and PRODUCT STORAGE ERROR (Vaccine went into 2-8 Celsius thaw state on or about 24-Dec-2021 and administered on 05-Feb-2022) in a 58-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 066H21A) for COVID-19 vaccination.     No Medical History information was reported.    On 05-Feb-2022 at 4:32 PM, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .25 milliliter. On 05-Feb-2022 at 4:32 PM, the patient experienced EXPIRED PRODUCT ADMINISTERED (Vaccine went into 2-8 Celsius thaw state on or about 24-Dec-2021 and administered on 05-Feb-2022). On an unknown date, the patient experienced PRODUCT STORAGE ERROR (Vaccine went into 2-8 Celsius thaw state on or about 24-Dec-2021 and administered on 05-Feb-2022). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Vaccine went into 2-8 Celsius thaw state on or about 24-Dec-2021 and administered on 05-Feb-2022) and PRODUCT STORAGE ERROR (Vaccine went into 2-8 Celsius thaw state on or about 24-Dec-2021 and administered on 05-Feb-2022) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Concomitant products were not reported. Patient received booster dose vaccination time was reported as 16:32:20. This vaccine was administered up until its manufacturing expiry date of 04-Apr-2022.  Treatment medications were not reported.
PT STATES SHE HAD A RED PAINFUL ARM AFTER RECEIVING A PNEUMOVAX.
Case number PHEH2014US018095, is an initial spontaneous report from a pharmacist received on 08 Sep 2014. This report refers to a 50-year-old female patient. Past medical history and concomitant medications were not reported. She was vaccinated with FLUVIRIN (batch number: 1412201) intramuscularly in arm on 03 Sep 2014. Post vaccination, she experienced pain and discomfort right away in the vaccination site and she said that the vaccination hurt. The event probably started and just continued and the pain went down her whole arm. The final outcome of the event was unknown. The seriousness and causality of the events were not reported.
Severe left arm pain below elbow are and now I have Tachycardia which I have never ever had before!
This is a spontaneous report received from a contactable reporter(s) (Physician). A 2-year-old male patient received BNT162b2 (BNT162B2), on 13Aug2022 at 11:00 as dose 1, single (Lot number: FT9142) at the age of 2 years, in right leg for covid-19 immunisation. The patient's relevant medical history included: "Face skin itching" (unspecified if ongoing), notes: Other medical history: Face skin itching since age 6 month. There were no concomitant medications. The following information was reported: PRODUCT ADMINISTERED AT INAPPROPRIATE SITE (non-serious) with onset 13Aug2022 at 11:00, outcome "unknown", described as "Vaccine site location Right leg  (site of vaccination)"; VACCINATION SITE RASH (non-serious), VACCINATION SITE PRURITUS (non-serious) all with onset 15Aug2022 at 12:00, outcome "recovered with sequelae" and all described as "Itching rash of the right thigh (site of vaccination)". Therapeutic measures were not taken as a result of vaccination site rash, vaccination site pruritus, product administered at inappropriate site. Additional information: Patient recovered with lasting effects. No treatment was given for adverse event. No covid prior and post vaccination.
pt recv vax 330PM woke up 4:30 from nap screaming a ear piercing screech;took to ER 6PM was given APAP w/cod then site finally calmed down;pt crying almost cont;swollen area @ inj site,inconsolable crying;erythema;
About 25-30 minutes after receiving the vaccine she broke out in hives, starting on face, chest, and arms.  The hives eventually covered her from head to toe.  She immediately returned to ED and was treated with Solumedrol 125mg  IM and sent home on medrol dose pack.
Patient came to the ED with cough, congestion, wheezing, and tightness in chest.  Patient was admitted to the hospital with Covid pneumonia and treated with remdesivir.
pt tested positive for COVID on 8/18; presented to ED on 8/24 hypoxic with confusion, SOB, coughing; placed on BIPAP; pneumothorax occurred; condition worsened where patient died in hospital
Is shot is mandatory for workers for employer. I got the shot by our corporate health nurse. 20 to 30 minutes later, I was short of breath, chest pain, lightheaded and dizzy, red eyes (very blood shot), coughing. I went to the nurse that gave me the shot and she advised I go to our ER (I was in our hospital at the time at work). The nurse walked me to the ER.
felt crummy after receiving all previous Moderna doses for 3 days; This spontaneous case was reported by a patient and describes the occurrence of FEELING ABNORMAL (felt crummy after receiving all previous Moderna doses for 3 days) in a 74-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 031H21A) for COVID-19 vaccination.     Patient had no allergies. Patient did not have COVID-19 in the past. No vaccines were given within 1 month prior to Moderna COVID-19 vaccine.  Concurrent medical conditions included Arthritis (15 years ago, worsening, but patient attribute it to a lot more walking than normal.), Blood pressure abnormal and Insomnia. Concomitant products included LISINOPRIL for Blood pressure abnormal, GABAPENTIN and TRAZODONE for Insomnia.   On 09-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 06-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 03-Dec-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced FEELING ABNORMAL (felt crummy after receiving all previous Moderna doses for 3 days). At the time of the report, FEELING ABNORMAL (felt crummy after receiving all previous Moderna doses for 3 days) had resolved.            Patient reported that she had gotten a list of excipients and additives when she had received the first doses. Patient did not seek medical care for AE. Patient concomitant medication included thyroid medicines (unspecified). No treatment medications were reported. The patient reported that she felt crummy after all Moderna vaccinations.   This case was linked to MOD-2022-663115 (Patient Link).
There was sweling at the site of injection and it hurt whenever the area was touched. The swelling and pain stopped after 2-3 days.
Information has been received from an 18 year old female healthcare worker with a history of becoming "non-responsive" after getting a pertussis vaccine who in January 2007, was vaccinate IM with her first dose of Gardasil.  There was no AE after the first dose.  In March 2007, the patient received her second IM dose of Gardasil.  An hour after the second dose, she developed an ocular migraine and then later a "regular migraine".  Medical attention was sought.  The patient recovered in March, 2007.  A month later (in April, 2007) she had a "smaller one".  The outcome of the April 2007 migraine was not reported.  Additional information has been requested.
A day later patient had reported to me that he was feeling tension on both sides of his chest, shoulder and back. Patient said he was not experiencing any pain but commented that he felt completely different than he has ever felt after receiving his third dose covid booster.  He discuss with me that he was scared that this shot did something to him. He discussed his concerns and then we started making appointments for him to get in to see the doctor for the tension he was having in his chest, back and shoulders. Patient also said he was feeling more tired and weak after receiving that third booster shot. Patient passed away March 19th, he suffered a heart attack at home.
intensely pruritic papular rash developed on back, chest, breasts, legs and arms the next after receiving vaccination. Pruritus became worse. She went to urgent care on 9/26 and was prescribed prednisone taper. no improvement so she came to report on 9/29.
Developed rash on Both anterior thighs within 24 hours after vaccine slightly pink maculopapules on both thighs.
Fatigue on day 1-2.  Chest pain and shortness of breath on day 3-4.   No fevers.  Symptoms fully resolved by day 5 without therapy.
exposed to a low temperature of 31.5 degrees Fahrenheit; This non-serious case was reported by a nurse via call center representative and described the occurrence of incorrect storage of drug in a 6-month-old female patient who received HAV (Havrix) (batch number PB5JA, expiry date 14-FEB-2025) for prophylaxis.   In JUN-2023, the patient received Havrix. On an unknown date, an unknown time after receiving Havrix, the patient experienced incorrect storage of drug (Verbatim: exposed to a low temperature of 31.5 degrees Fahrenheit). The outcome of the incorrect storage of drug was unknown.   Additional Information: GSK Receipt date: 3-AUG-2023 The reporter reported that the Havrix vaccines exposed to a low temperature of 31.5 degrees Fahrenheit on 15th June 2023 was administered between 15th June 2023 and 21st June 2023. Reporter did not have specific date of administration for each patient. The reporter reported that at the time of reporting, the dose had not been repeated. The vaccine administration facility was the same as primary reporter. The reporter consented to follow up. The reporter reported that the administered Havrix vaccines exposed to a low temperature of 31.5 degrees Fahrenheit, which led to incorrect storage of drug. This case was 1 of 9 cases, reported by same reporter.; Sender's Comments:  US-GSK-US2023105916:same reporter US-GSK-US2023105926:same reporter US-GSK-US2023105918:same reporter US-GSK-US2023105917:same reporter US-GSK-US2023105923:same reporter US-GSK-US2023105925:same reporter US-GSK-US2023105928:same reporter US-GSK-US2023105927:same reporter
Fatigue; Depression; This is a spontaneous report from a non-contactable consumer, the patient. A 42-year-old female patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: ER8730), via an unspecified route of administration on an unknown date (at the age of 42-years-old), as a single dose for COVID-19 immunisation. Medical history and concomitant medications were not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On an unknown date, the patient experienced fatigue and depression. The patient did not receive any treatment for the events fatigue and depression. The clinical outcomes of the events fatigue and depression were not resolved at the time of this report.  No follow-up attempts are needed. No further information is expected.
Multiple Sclerosis; Decreased eyesight; This spontaneous case was reported by a health care professional and describes the occurrence of MULTIPLE SCLEROSIS (Multiple Sclerosis) in a 24-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    In February 2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced MULTIPLE SCLEROSIS (Multiple Sclerosis) (seriousness criterion medically significant) and VISUAL IMPAIRMENT (Decreased eyesight). At the time of the report, MULTIPLE SCLEROSIS (Multiple Sclerosis) and VISUAL IMPAIRMENT (Decreased eyesight) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Patient was treated with steroid for decreased eyesight, and was recovered  70%. concomitant product details not provided.  Very limited information regarding these events has been provided at this time. Further information has been requested.; Sender's Comments: Very limited information regarding these events has been provided at this time. Further information has been requested.
About 10 min after vaccination, developed persistent tongue tingling. No other symptoms noted. Normal exam, including no visible swelling of lips or tongue. Vital signs normal. Symptoms improved within the next ~45 min (about 90% better) although had not completely resolved prior to leaving clinic.
REDNESS IN LEFT ARM; SORNESS IN RIGHT ARM/SORENESS IN LEFT ARM; KNOT THE SIZE OF A ORANGE IN LEFT ARM; knot is hot to touch; This spontaneous case was reported by a consumer and describes the occurrence of ERYTHEMA (REDNESS IN LEFT ARM), PAIN IN EXTREMITY (SORNESS IN RIGHT ARM/SORENESS IN LEFT ARM), MASS (KNOT THE SIZE OF A ORANGE IN LEFT ARM) and FEELING HOT (knot is hot to touch) in a 72-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 001B21A) for COVID-19 vaccination.     No Medical History information was reported.   On 14-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 15-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 14-Feb-2021, the patient experienced ERYTHEMA (REDNESS IN LEFT ARM), PAIN IN EXTREMITY (SORNESS IN RIGHT ARM/SORENESS IN LEFT ARM), MASS (KNOT THE SIZE OF A ORANGE IN LEFT ARM) and FEELING HOT (knot is hot to touch). At the time of the report, ERYTHEMA (REDNESS IN LEFT ARM), PAIN IN EXTREMITY (SORNESS IN RIGHT ARM/SORENESS IN LEFT ARM), MASS (KNOT THE SIZE OF A ORANGE IN LEFT ARM) and FEELING HOT (knot is hot to touch) outcome was unknown. Not Provided          Concomitant medication use was not reported.   Treatment information was not reported. Action taken with mRNA-123 is not applicable.
RN was administering a Pneumovax 23 to a patient from a prefilled syringe.  The medication leaked around the base of the needle (23g x 1) where the needle meets the attachment to the syringe at the junction of the white and blue.  The patient stated she could feel the medication leaking down her arm and RN saw it coming out. RN stopped administering the medication.  A second dose was administered to the patient.
Lethargy, mildly pruratic blotchy rash. (R) temple (2cm diam.) and (R)cheek (4cm diam.). Appearance similar to non-urticaria rxn.
This spontaneous report was received from a nurse and refers to a unspecified patient of unknown age and gender. There was no information about patient's concomitant medications and pertinent medical history reported. On an unknown date, the patient was vaccinated with a dose of improperly stored ROTATEQ orally, lot number reported as M035385 with expiration date 08-APR-2018 or lot number M032642 with expiration date 04-MAR-2018, (dose was not reported) for prophylaxis. The ROTATEQ  was exposed to temperatures between 8 Celsius and 25 Celsius during 5 hours and 35 minutes. The vaccine was not exposed to previous temperature excursion. Data logger was filed. No adverse effect was reported. This is one of two reports from the same source. Additional information has been requested.; Sender's Comments: US-009507513-1702USA007901:
Fever; Chills; Fatigue; Muscle aches; This is a spontaneous report from a contactable consumer, the patient. A 45-year-old non-pregnant female patient received unknown dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on 01Apr2021 at 12:00 (at the age of 45-year-old) as a single dose for COVID-19 immunisation. Medical history included ulcerative colitis. The patient was allergic to sulpha drugs since an unknown date. Concomitant medications included minerals NOS, vitamins NOS (CENTRUM); calcium carbonate (CALTRATE); and levothyroxine sodium (SYNTHROID) all from an unknown date for an unknown indication. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 01Apr2021 at 22:00, the patient experienced fever, chills, fatigue and muscle aches. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the events. The clinical outcome of the events fever, chills, fatigue and muscle aches were recovering at the time of this report.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Developed painful red arm, got worse the next day, took Benadryl and it made it less tight. 11 x 11cm slight redness, slight warmth but predominately induration, got better on 4/17/06 no more redness, pain or soreness.